ReviewCurrent oncology (Toronto, Ont.)2022
Innovations in the Management of Vaginal Cancer.
Review in Current oncology (Toronto, Ont.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 17 citations in OpenAlex.
- Primary endometrioid adenocarcinoma of the vagina after total hysterectomy for adenomyosis: A case report.Oncology letters · 2026Article
- Prognostic factors for lymph node infestation, long-term survival and recurrence rates in patients with vaginal cancer: a population-based study in Germany.Journal of cancer research and clinical oncology · 2026Article
- Multimodal Ultrasound in Evaluating Radiotherapy Efficacy for Vaginal Squamous Cell Carcinoma: A Case Report.Current medical imaging · 2026Article
- Advances in Photodynamic Treatment of Precancerous and Cancerous Gynecological Diseases.Cancers · 2025Review
- The implication of aberrant NRF2 activation in management of female cancers.Frontiers in oncology · 2025Review
- Evaluation of Bi-layer Silk Fibroin Grafts for Inlay Vaginoplasty in a Rat Model.Tissue engineering and regenerative medicine · 2024Article
- Vaginal microbiota and gynecological cancers: a complex and evolving relationship.Infectious agents and cancer · 2024Review
- The Role of Urothelial Cancer-Associated 1 in Gynecological Cancers.Current issues in molecular biology · 2024Review
- Article
- Primary vaginal cancer after hysterectomy for benign conditions: a systematic review of the literature.Frontiers in oncology · 2024Review
- Development and validation of models for predicting the overall survival and cancer-specific survival of patients with primary vaginal cancer: A population-based retrospective cohort study.Frontiers in medicine · 2022Article
- Pembrolizumab in Vaginal Carcinoma: A Case Report and Review of the Literature.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary vaginal cancer is a rare gynecologic malignancy. Given the rarity of the disease, standardized approaches to management are limited, and a great variety of therapeutic conditions are endorsed. This paper reviews advances in surgical approaches, radiation, chemoradiation, and immunotherapy. Advances in surgical management including the increasing use of laparoscopic and endoscopic approaches, as well as the novel techniques in vaginal reconstruction, are reviewed. Concurrent chemoradiation remains a mainstay of treatment for vaginal cancer and has improved local control of disease and overall survival. Additionally, with metastatic disease or situations where toxicity from CCRT is unacceptable, systemic therapies including immunotherapy approaches are reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.